vs
Doximity, Inc.（DOCS）与Prestige Consumer Healthcare Inc.（PBH）财务数据对比。点击上方公司名可切换其他公司
Prestige Consumer Healthcare Inc.的季度营收约是Doximity, Inc.的1.5倍（$283.4M vs $185.1M），Doximity, Inc.净利率更高（33.3% vs 16.5%，领先16.8%），Doximity, Inc.同比增速更快（9.8% vs -2.4%），过去两年Doximity, Inc.的营收复合增速更高（25.2% vs 1.2%）
Doximity Inc成立于2010年，是面向医疗专业人士的线上社交服务平台，为平台会员提供精选医疗资讯、远程医疗工具，以及病例协作相关功能，助力医疗从业者高效交流信息、开展诊疗相关工作。
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
DOCS vs PBH — 直观对比
营收规模更大
PBH
是对方的1.5倍
$185.1M
营收增速更快
DOCS
高出12.1%
-2.4%
净利率更高
DOCS
高出16.8%
16.5%
两年增速更快
DOCS
近两年复合增速
1.2%
损益表 — Q3 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $185.1M | $283.4M |
| 净利润 | $61.6M | $46.7M |
| 毛利率 | 89.9% | 55.5% |
| 营业利润率 | 38.9% | 29.1% |
| 净利率 | 33.3% | 16.5% |
| 营收同比 | 9.8% | -2.4% |
| 净利润同比 | -18.1% | -23.5% |
| 每股收益（稀释后） | $0.31 | $0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCSPBH
| Q4 25 | $185.1M | $283.4M | ||
| Q3 25 | $168.5M | $274.1M | ||
| Q2 25 | $145.9M | $249.5M | ||
| Q1 25 | $138.3M | $296.5M | ||
| Q4 24 | $168.6M | $290.3M | ||
| Q3 24 | $136.8M | $283.8M | ||
| Q2 24 | $126.7M | $267.1M | ||
| Q1 24 | $118.1M | $277.0M |
净利润DOCSPBH
| Q4 25 | $61.6M | $46.7M | ||
| Q3 25 | $62.1M | $42.2M | ||
| Q2 25 | $53.3M | $47.5M | ||
| Q1 25 | $62.5M | $50.1M | ||
| Q4 24 | $75.2M | $61.0M | ||
| Q3 24 | $44.2M | $54.4M | ||
| Q2 24 | $41.4M | $49.1M | ||
| Q1 24 | $40.6M | $49.5M |
毛利率DOCSPBH
| Q4 25 | 89.9% | 55.5% | ||
| Q3 25 | 90.3% | 55.3% | ||
| Q2 25 | 89.2% | 56.2% | ||
| Q1 25 | 89.5% | 57.3% | ||
| Q4 24 | 91.6% | 55.5% | ||
| Q3 24 | 90.0% | 55.5% | ||
| Q2 24 | 89.3% | 54.7% | ||
| Q1 24 | 89.4% | 54.8% |
营业利润率DOCSPBH
| Q4 25 | 38.9% | 29.1% | ||
| Q3 25 | 37.8% | 29.1% | ||
| Q2 25 | 37.4% | 28.8% | ||
| Q1 25 | 35.2% | 29.8% | ||
| Q4 24 | 47.4% | 31.7% | ||
| Q3 24 | 38.8% | 29.7% | ||
| Q2 24 | 36.4% | 27.0% | ||
| Q1 24 | 35.5% | 29.7% |
净利率DOCSPBH
| Q4 25 | 33.3% | 16.5% | ||
| Q3 25 | 36.8% | 15.4% | ||
| Q2 25 | 36.5% | 19.0% | ||
| Q1 25 | 45.2% | 16.9% | ||
| Q4 24 | 44.6% | 21.0% | ||
| Q3 24 | 32.3% | 19.2% | ||
| Q2 24 | 32.7% | 18.4% | ||
| Q1 24 | 34.4% | 17.9% |
每股收益（稀释后）DOCSPBH
| Q4 25 | $0.31 | $0.97 | ||
| Q3 25 | $0.31 | $0.86 | ||
| Q2 25 | $0.27 | $0.95 | ||
| Q1 25 | $0.31 | $1.00 | ||
| Q4 24 | $0.37 | $1.22 | ||
| Q3 24 | $0.22 | $1.09 | ||
| Q2 24 | $0.21 | $0.98 | ||
| Q1 24 | $0.20 | $0.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.8M | $62.4M |
| 总债务越低越好 | — | $1.0B |
| 股东权益账面价值 | $979.3M | $1.8B |
| 总资产 | $1.2B | $3.5B |
| 负债/权益比越低杠杆越低 | — | 0.56× |
8季度趋势，按日历期对齐
现金及短期投资DOCSPBH
| Q4 25 | $64.8M | $62.4M | ||
| Q3 25 | $169.2M | $119.1M | ||
| Q2 25 | $137.3M | $139.5M | ||
| Q1 25 | $209.6M | $97.9M | ||
| Q4 24 | $165.3M | $50.9M | ||
| Q3 24 | $184.2M | $51.5M | ||
| Q2 24 | $111.4M | $34.3M | ||
| Q1 24 | $96.8M | $46.5M |
总债务DOCSPBH
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $993.1M | ||
| Q2 25 | — | $992.7M | ||
| Q1 25 | — | $992.4M | ||
| Q4 24 | — | $992.0M | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
股东权益DOCSPBH
| Q4 25 | $979.3M | $1.8B | ||
| Q3 25 | $1.1B | $1.8B | ||
| Q2 25 | $1.0B | $1.9B | ||
| Q1 25 | $1.1B | $1.8B | ||
| Q4 24 | $1.0B | $1.8B | ||
| Q3 24 | $961.2M | $1.7B | ||
| Q2 24 | $913.6M | $1.7B | ||
| Q1 24 | $901.4M | $1.7B |
总资产DOCSPBH
| Q4 25 | $1.2B | $3.5B | ||
| Q3 25 | $1.3B | $3.4B | ||
| Q2 25 | $1.2B | $3.4B | ||
| Q1 25 | $1.3B | $3.4B | ||
| Q4 24 | $1.2B | $3.3B | ||
| Q3 24 | $1.1B | $3.3B | ||
| Q2 24 | $1.1B | $3.3B | ||
| Q1 24 | $1.1B | $3.3B |
负债/权益比DOCSPBH
| Q4 25 | — | 0.56× | ||
| Q3 25 | — | 0.54× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | — | 0.54× | ||
| Q4 24 | — | 0.55× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | — | 0.65× | ||
| Q1 24 | — | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.9M | $78.3M |
| 自由现金流经营现金流 - 资本支出 | — | $75.3M |
| 自由现金流率自由现金流/营收 | — | 26.6% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | 0.99× | 1.68× |
| 过去12个月自由现金流最近4个季度 | — | $267.2M |
8季度趋势，按日历期对齐
经营现金流DOCSPBH
| Q4 25 | $60.9M | $78.3M | ||
| Q3 25 | $93.9M | $57.5M | ||
| Q2 25 | $62.1M | $79.0M | ||
| Q1 25 | $98.5M | $61.8M | ||
| Q4 24 | $65.2M | $65.1M | ||
| Q3 24 | $68.3M | $69.8M | ||
| Q2 24 | $41.2M | $54.8M | ||
| Q1 24 | $63.9M | $66.9M |
自由现金流DOCSPBH
| Q4 25 | — | $75.3M | ||
| Q3 25 | — | $55.4M | ||
| Q2 25 | — | $78.2M | ||
| Q1 25 | — | $58.4M | ||
| Q4 24 | — | $63.5M | ||
| Q3 24 | — | $67.8M | ||
| Q2 24 | — | $53.6M | ||
| Q1 24 | — | $63.8M |
自由现金流率DOCSPBH
| Q4 25 | — | 26.6% | ||
| Q3 25 | — | 20.2% | ||
| Q2 25 | — | 31.3% | ||
| Q1 25 | — | 19.7% | ||
| Q4 24 | — | 21.9% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 20.1% | ||
| Q1 24 | — | 23.0% |
资本支出强度DOCSPBH
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | 0.0% | 1.2% | ||
| Q4 24 | 0.0% | 0.5% | ||
| Q3 24 | 0.0% | 0.7% | ||
| Q2 24 | 0.0% | 0.4% | ||
| Q1 24 | 0.0% | 1.1% |
现金转化率DOCSPBH
| Q4 25 | 0.99× | 1.68× | ||
| Q3 25 | 1.51× | 1.36× | ||
| Q2 25 | 1.16× | 1.66× | ||
| Q1 25 | 1.58× | 1.23× | ||
| Q4 24 | 0.87× | 1.07× | ||
| Q3 24 | 1.55× | 1.28× | ||
| Q2 24 | 1.00× | 1.12× | ||
| Q1 24 | 1.57× | 1.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
